Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.71 |
| ▸ | EGFR | P00533 | 3/20 | 0.71 |
| ▸ | KIT | P10721 | 2/20 | 0.71 |
| ▸ | NEK2 | P51955 | 2/20 | 0.71 |
| ▸ | MELK | Q14680 | 2/20 | 0.71 |
| ▸ | PRKAA1 | Q13131 | 10/20 | 0.64 |
| ▸ | PRKAA2 | P54646 | 9/20 | 0.64 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31672460 | 1.00 | KDR (0.71) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL13755260 | 0.92 | KDR (0.71) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL2114504 | 0.90 | KDR (0.79) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL2114517 | 0.90 | KDR (0.75) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL2116631 | 0.90 | KDR (0.71) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL31672507 | 0.90 | KDR (0.71) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL31672444 | 0.90 | KDR (0.75) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL31672529 | 0.90 | KDR (0.79) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL31672538 | 0.88 | PRKAA1 (0.69) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL2117345 | 0.88 | PRKAA1 (0.69) | KDRPDGFRBFGFR1EGFRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | US | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | KDR 395/4885PDGFRB 555/4885FGFR1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.